Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Cryoablation Offers Local Control for Extra-Abdominal Desmoid Tumors
Cryoablation Offers Local Control for Extra-Abdominal Desmoid Tumors
Project Oncology®
Cryoablation Offers Local Control for Extra-Abdominal Desmoid Tumors
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
MinuteCE®
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
KRAS G12C Biology: Why Is This Mutation Different?
KRAS G12C Biology: Why Is This Mutation Different?
MinuteCE®
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
MinuteCE®
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
MinuteCE®
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
MinuteCE®
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
News
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
A.J. Gelderblom, MD, PhD
- A.J. Gelderblom, MD, PhD
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Project Oncology®
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Alexandria May, PharmD, BCPS; Neil M. Iyengar, MD
- Alexandria May, PharmD, BCPS
- Neil M. Iyengar, MD

Medical News

Medical News
Thyroid Cancer: Thermal Ablation vs Surgery at Five Years
11/11/2026
Read more
Medical News
Five-Year Colonoscopy After High-Risk Adenomas Meets Interim Noninferiority
11/11/2026
Read more
Medical News
DCIS Surgery: Survival Associations in Women 70 and Older
11/10/2026
Read more
Medical News
Timely ED Pain Care Linked to Relief in Terminal Cancer Cohort
11/09/2026
Read more

CME/CE

From Biopsy to Results: Building a Reflex-Ready Testing Workflow
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
MinuteCE®
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
0.75 program credits
- Gerard A. Silvestri MD, MS
0.75 program credits
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
CME/CE
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
0.50 credits
- Jennifer R. Brown, MD, PhD
0.50 credits
CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits

Clinical Practice

CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Project Oncology®
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Alexandria May, PharmD, BCPS; Tara Graff, DO, MS
- Alexandria May, PharmD, BCPS
- Tara Graff, DO, MS
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
MinuteCE®
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
CME/CE
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
Amer Zeidan, MBBS; Guillermo Garcia-Manero, MD
0.50 credits
- Amer Zeidan, MBBS
- Guillermo Garcia-Manero, MD
0.50 credits
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
On the Frontlines of Non-Small Cell Lung Cancer
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
Ryan Quigley; Alexander Drilon, MD
- Ryan Quigley
- Alexander Drilon, MD

Programs

Making the Most of Biomarker Testing in NSCLC
Making the Most of Biomarker Testing in NSCLC
On the Frontlines of Non-Small Cell Lung Cancer
Making the Most of Biomarker Testing in NSCLC
Steve Jackson, PharmD; Angel Qin, MD
- Steve Jackson, PharmD
- Angel Qin, MD
Biomarker Testing After Progression in HR+/HER2- mBC
Biomarker Testing After Progression in HR+/HER2- mBC
On the Frontlines of Metastatic Breast Cancer
Biomarker Testing After Progression in HR+/HER2- mBC
Alexandria May, PharmD, BCPS; Adam Brufsky, MD, PhD
- Alexandria May, PharmD, BCPS
- Adam Brufsky, MD, PhD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
Solange Peters, MD, PhD
0.50 credits
- Solange Peters, MD, PhD
0.50 credits
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Clinician's Roundtable
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Brian P. McDonough, MD, FAAFP; David A. Johnson, MD, FACG, FACP
- Brian P. McDonough, MD, FAAFP
- David A. Johnson, MD, FACG, FACP